10-Q: Marpai Faces Going Concern Amid Revenue Decline

Marpai, Inc. reports a significant reduction in net loss for Q2 2025, but faces substantial doubt about its ability to continue as a going concern due to declining revenue and negative working capital.

Summary

• Marpai, Inc. reported a net loss of $7.4 million for the six months ended June 30, 2025, a significant improvement from a $17.4 million net loss in the same period of 2024.
• Revenue for the six months ended June 30, 2025, decreased by 30.9% to $10.1 million, down from $14.6 million in the prior year, primarily due to customer turnover.
• The company had an accumulated deficit of approximately $106.3 million and negative working capital of approximately $9.4 million as of June 30, 2025.
• Management has determined that the company's liquidity condition raises substantial doubt about its ability to continue as a going concern through the next twelve months.
• Operating expenses were significantly reduced, with general and administrative expenses decreasing by 33.3% and sales and marketing expenses decreasing by 46.4% for the six-month period.
• Net cash used in operating activities improved to $3.3 million for the six months ended June 30, 2025, compared to $6.7 million in the prior year.
• The company continues to rely on proceeds from issuing convertible notes and equity, having received $3.0 million from a JGB investment in January 2025 and $730 thousand from a private placement in May 2025.
• Subsequent to the quarter end, Marpai completed two additional private placements in July 2025, raising capital by issuing 130,208 shares at $1.152 per share and 603,640 shares at $1.0768 per share, with significant participation from an entity controlled by the CEO.

Sentiment

Score: 3

Explanation: While the company significantly reduced its net loss through cost-cutting, the substantial decline in revenue due to customer turnover, coupled with negative working capital and a 'going concern' warning, indicates a precarious financial position and significant operational challenges. The ongoing reliance on capital raises, including from related parties, highlights persistent liquidity issues.

Positives

• Net loss significantly reduced by 57.2% to $7.4 million for the six months ended June 30, 2025, compared to $17.4 million in the prior year.
• Operating loss decreased by 64.2% to $5.9 million for the six months ended June 30, 2025, from $16.3 million in the prior year.
• Net cash used in operating activities decreased by 50.4% to $3.3 million for the six months ended June 30, 2025, indicating improved cash burn efficiency.
• General and administrative expenses decreased by $2.3 million (33.3%) for the six-month period due to streamlining TPA operations.
• Sales and marketing expenses decreased by $482 thousand (46.4%) for the six-month period due to headcount reduction and strategic realignment.
• Facilities expenses decreased by $574 thousand (64.9%) for the six-month period due to strategic decommissioning of unutilized facilities.
• Received $500 thousand in cash from the sale of a business unit during the six months ended June 30, 2025.

Negatives

• Revenue decreased by 30.9% to $10.1 million for the six months ended June 30, 2025, primarily due to customer turnover.
• The company has an accumulated deficit of approximately $106.3 million as of June 30, 2025.
• Negative working capital of approximately $9.4 million as of June 30, 2025.
• Management has determined that the company's liquidity condition raises substantial doubt about its ability to continue as a going concern.
• Information technology expenses increased by 14.9% for the six-month period.
• Interest expense, net, increased by 28.6% to $1.6 million for the six months ended June 30, 2025.
• Concentration of accounts receivable with three customers accounting for 34.8%, 12.0%, and 11.4% respectively, as of June 30, 2025.

Risks

• Substantial doubt about the ability to continue as a going concern due to accumulated deficit, negative working capital, and ongoing net losses and negative operating cash flows.
• Inability to raise additional capital through equity or debt funding on favorable terms, or at all, which could materially and adversely impact operations and product investment.
• Potential for significant dilution to existing stockholders if additional capital is raised through equity issuance.
• Risk of being forced to scale back operations or divest some or all assets if unable to raise sufficient capital.
• Revenue concentration risk, as the loss of major customers could significantly decrease revenue and adversely affect results of operations.
• Uncertainty and potential adverse impact on business from the ongoing review of strategic alternatives, which may be costly, time-consuming, and disruptive.
• Difficulty attracting and retaining qualified personnel and key employees due to perceived uncertainties related to the company's future.
• Exposure to fluctuations due to changes in the exchange rate of the New Israeli Shekel (NIS) versus the U.S. Dollar.
• Impact of global macroeconomic environment, including inflationary pressures, supply chain disruptions, tariffs, social and political issues, regulatory matters, geopolitical tensions, and global security issues.

Future Outlook

The company projects a need for additional capital to fund current operations and capital investment requirements until it achieves cash self-sufficiency. Anticipated sources of capital include equity sales, debt issuance, or the sale of non-strategic assets. The company is also evaluating the impact of recently issued accounting pronouncements (ASU 2023-09, 2024-03, 2024-04) and the 'One Big Beautiful Bill Act' (H.R. 1) on its financial statements.

Management Comments

• Our mission is to positively change healthcare for the benefit of our self-insured employer clients, their employees (members), and healthcare providers.
• We continue to monitor the effects of the global macroeconomic environment, including increasing inflationary pressures, supply chain disruptions, tariffs, social and political issues, regulatory matters, geopolitical tensions, and global security issues, and are mindful of inflationary pressures on our cost base.
• We currently project that we will need additional capital to fund our current operations and capital investment requirements until we scale to a revenue level that permits cash self-sufficiency.
• The decline in revenue is primarily due to customer turnover; the market is evolving, and we are adapting our approach to better serve our customers' needs.
• The decrease in general and administrative expenses is due to actions taken throughout 2024 to streamline the company's TPA operations.
• The decrease in sales and marketing expenses is due to actions taken in the second quarter of 2024, including a headcount reduction, to strategically realign our focus and eliminate certain departments to improve overall efficiency and resource allocation.
• The decrease in facilities expenses was due to the strategic decommissioning of unutilized facilities.
• Management continues to evaluate additional funding alternatives and is seeking to raise additional funds through the issuance of equity or debt securities.
• Our Board of Directors, supported by our management team, is considering exploring strategic alternatives focused on maximizing shareholder value, which may include a strategic investment financing, a business combination, or a sale of the company.

Industry Context

Marpai operates in the U.S. healthcare third-party administration (TPA) market, serving self-insured employer groups. The company aims to differentiate itself by combining payer licenses and processes with advanced technology to lower healthcare costs and improve outcomes. Management acknowledges an evolving market and is adapting its approach to customer needs, while also monitoring broader macroeconomic factors like inflation and geopolitical tensions that could impact its cost base and customer preferences.

Management Changes

Corporate Governance

Legal Proceedings

• No currently pending legal proceedings that are believed to have a material adverse impact on the business or condensed consolidated financial statements.

Related Party Transactions

• On January 16, 2024, entered a securities purchase agreement with HillCour Investment Fund LLC (controlled by CEO Damien Lamendola) and one director to sell 1,322,100 shares of common stock in a private placement.
• On March 7, 2024, entered a securities purchase agreement with HillCour to sell 910,000 shares of common stock in a private placement.
• CEO Damien Lamendola provided a guarantee for the funding agreement with Libertas Funding, LLC in February 2024.
• On August 28, 2024, entered a securities purchase agreement with two investors, including HillCour, to sell 2,702,702 shares of common stock in a private placement, with HillCour purchasing 1,351,351 shares.
• On December 5, 2024, entered a Securities Purchase Agreement with four investors, including Chairman Yaron Eitan, CFO Steve Johnson, and President and Chief Operating Officer John Powers, to sell 621,194 shares of common stock in a private placement.
• On January 28, 2025, a director received a 600,000 RSU award in connection with being a personal guarantor on new financing.
• On July 17, 2025, entered a securities purchase agreement with two investors, including HillCour, to sell 130,208 shares of common stock in a private placement, with HillCour purchasing 86,805 shares.
• On July 29, 2025, entered a Securities Purchase Agreement with three investors, including HillCour, to sell 603,640 shares of common stock in a private placement, with HillCour purchasing 371,470 shares.

Stakeholder Impact

• Shareholders face potential significant dilution from ongoing and future equity capital raises.
• Shareholders are subject to increased uncertainty and potential stock price volatility due to the company's 'going concern' warning and the exploration of strategic alternatives.
• Employees may be impacted by further headcount reductions or scaling back of operations if the company fails to secure additional funding.
• Customers are experiencing 'customer turnover,' indicating potential dissatisfaction or competitive pressures, which the company is attempting to address by adapting its approach.
• Creditors face elevated risk due to the company's substantial accumulated deficit, negative working capital, and the 'going concern' warning, which suggests challenges in meeting future obligations.

Next Steps

• Raise additional capital through the issuance of equity or debt securities.
• Potentially sell non-strategic assets to fund ongoing operations.
• Explore strategic alternatives, including strategic investment financing, business combination (merger), or a sale of the company.
• Continue adapting approach to better serve customer needs in an evolving market.
• Evaluate the impact of new accounting standards (ASU 2023-09, 2024-03, 2024-04) on consolidated financial statements.
• Evaluate the impact of 'The One Big Beautiful Bill Act' (H.R. 1) on consolidated financial statements.

Key Dates

Recommendation

The company faces a 'going concern' warning, indicating severe financial distress and a high risk of business failure without significant intervention. Despite a reduction in net loss, this was largely driven by cost-cutting and prior-year impairment charges, while core revenue continues to decline significantly due to customer turnover. The persistent negative working capital and heavy reliance on continuous, dilutive capital raises, including from related parties, underscore an unsustainable financial model. The exploration of strategic alternatives further highlights the precarious situation, making the stock a high-risk investment with substantial downside potential.

Keywords

Healthcare administration, TPA, Self-insured employers, Health benefits, Going concern, Capital raise, Private placement, Revenue decline, Net loss reduction, Strategic alternatives, Corporate governance, SEC filing, Marpai